田内 哲三 医師|ドクターズプロフィール

      • 田内 哲三

        たうち てつぞう

        血液内科 部長

      【専門分野/得意な領域】
      造血器腫瘍・慢性骨髄性白血病

    • 【専門医・指導医】
      日本血液学会専門医及び指導医
      日本内科学会認定医・指導医

専門医/学位取得

1986年 東京医科大学医学部医学科卒業
1986年 東京医科大学内科第一講座入局
1992年 米国インディアナ大学へ留学
1992年 医学博士
1995年 東京医科大学助手として内科学第一講座勤務
2001年 東京医科大学講師として内科学第一講座勤務
2008年 東京医科大学准教授として血液内科学分野勤務
日本血液学会代議員
日本血液学会専門医試験作成委員
日本内科学科会員
日本癌学会会員

公職/賞罰

その他 Japan Adult Leukemia Study Group (JALSG) 常設委員会付随研究審査委員
文部科学省科学技術・学術政策研究所 専門調査員 2017年3月まで
1992年6月 東京医科大学同窓会ヒポクラテス賞
1997年6月 東京医科大学同窓会奨励賞受賞
2001年5月 東京医科大学稲垣教育賞
2003年10月 日本白血病基金荻村孝特別賞

受領した競争的研究助成金

  1. 2017年度, ノバルティス ファーマ研究助成, iPS細胞を用いた造血器腫瘍発症機序の解明と新規治療法の開発, 代表
  2. 2015年度, 公益財団法人 東京医科大学がん研究事業団 がん研究助成金, iPS細胞を用いた癌性幹細胞を標的とした新規分子標的薬の開発, 代表
  3. 2014年度, 2015年度, Pfizer Inc, a Delaware corporation with an address at 235 East 42nd Street, New York, New York 10017 (“Pfizer”) Research Fund, Patient derived iPSC models of myelodysplastic syndrome as a platform to study SMO inhibition in MDS, 代表
  4. 2009年度, 2010年度, 厚生労働省創薬基盤推進研究事業, 成人白血病の難治機構の分子レベルでの解明とそれに基づく分子標的治療の開発に関する研究, 分担
  5. 2007年度, 2008年度, 多施設共同研究に登録された白血病の検体収集と中央保存システムの確立, 分担
  6. 2007年度, 2008年度, 文部科学省科学研究費補助金基盤研究(C), 慢性骨髄性白血病におけるDNA修復エラーの分子病態と微少残存病変の制御の研究, 代表
  7. 2005年度, 2006年度, 2007年度, 文部科学省科学研究費補助金基盤研究(C), テロメア・テロメラーゼを介した造血器腫瘍の分子病態の解析と分子標的療法, 代表
  8. 2004年度, 文部科学省科学研究費補助金基盤研究(C), テロメラーゼを介した造血器腫瘍の分子病態の解析と分子標的療法,代表
  9. 2003年度, 公益信託日本白血病研究助成金, テロメラーゼ活性分子、hTERTを標的とした造血器腫瘍の分子標的療法の開発,代表
  10. 2003年度, ノバルティス科学振興財団研究助成金, テロメラーゼ活性分子、hTERTを標的とした造血器腫瘍の分子標的療法の開発,代表
  11. 2001年度, 2002年度, 2003年度, 文部科学省科学研究費補助金基盤研究(C), テロメラーゼ活性分子、hTERTを標的とした造血器腫瘍の分子標的療法の開発, 代表
  12. 1999年度, 2000年度, 文部省科学研究費補助金奨励研究(A), CIS1ノックアウトマウスを用いた慢性骨髄性白血病の病態の分子機構の解析,代表
  13. 1997年度, 1998年度, 文部省科学研究費補助金奨励研究(A), BCR-ABL変異体を用いた慢性骨髄性白血病の病態の分子機構の解析, 代表
  14. 1996年度, 文部省科学研究費補助金奨励研究(A), BCR-ABL変異体を用いた機能ドメインの解析と細胞内分子の相互作用, 代表

著書

  1. 田内哲三, 慢性骨髄性白血病の発症機構, 造血器腫瘍アトラス改正5版, 谷脇雅史, 横田昇平, 黒田純也, 日本医事新報社, 2016, 292-297
  2. 田内哲三, 分子標的薬, 血液科研修ノート, 永井良三, 診断と治療社, 2016, 142-146
  3. 田内哲三, 第2世代ABLチロシンキナーゼ阻害剤の長期副作用, 白血病診療Q&A, 松村到, 中外医学社, 2015, 207-213
  4. 田内哲三, 慢性骨髄性白血病, 今日の治療指針, 山口徹, 北原光夫, 医学書院, 2014, 636-638
  5. 田内哲三, 慢性骨髄性白血病, 血液疾患最新の治療, 直江知樹, 小澤敬也, 中尾真二, 南江堂, 2014, 138-143
  6. 田内哲三, 慢性骨髄性白血病、骨髄異形成症候群、多血症, 内科疾患最新の治療:明日への指針, 高久文麿, 南江堂, 2014, 1490-1497
  7. 田内哲三, イマチニブ耐性の病態と治療指針, EBM 血液疾患の治療 2015-2016, 金倉譲, 木崎昌弘, 鈴木律朗, 神田善申, 中外医学社, 2011, 160-165
  8. 田内哲三, 慢性骨髄性白血病, Annual Review 血液, 高久文麿, 中外医学社, 2012, 116-123
  9. 田内哲三, 大屋敷一馬, メシル酸イマチニブ, がん化学療法分子標的治療update, 西条長宏, 西尾和人,中外医学社, 2009, 144-148
  10. 田内哲三, 大屋敷一馬, 慢性骨髄性白血病(CML), WHO分類第4版による白血病、リンパ系腫瘍の病態学, 木崎昌弘, 田丸純一, 中外医学社, 2008, 21-28
  11. 田内哲三, 好酸球増多症候群, 臨床アレルギー学, 宮本昭正, 南江堂, 2007, 452-453
  12. 田内哲三, 大屋敷一馬, CMLに対する第2世代型チロシンキナーゼ阻害剤(Dasatinib, Nilotinib)の治療の位置づけ, EBM血液疾患の治療2008-2009, 押味和夫, 別所正美, 岡本真一郎, 加藤淳, 中外医学社, 2007, 236-241
  13. Tauchi T, Ohyashiki JH, Ohyashiki K, Telomerase Inhibition Combined with Other Chemotherapeutic Reagents to Enhance Anti-Cancer Effect., Telomerase Inhibition, Andrews LG, Tollefsbol TO, Human Press, 2007, 181-189
  14. 田内哲三, 大屋敷一馬, イマチニブ耐性化機序と克服, 別冊:新しい診断と治療のABC(血液)慢性骨髄増殖疾患, 大屋敷一馬, 最新医学社, 2004, 58-67
  15. 田内哲三, 大屋敷一馬, 慢性骨髄性白血病の分子病態と治療, 造血器悪性腫瘍へのアプローチ, 北村幸彦, 朝長万左男, 金倉譲, 医学ジャーナル, 2003, 88-98
  16. 田内哲三, 大屋敷一馬, チロシンキナーゼ阻害剤ImatinibによるPh陽性白血病の分子標的療法, 平井久丸, 医学の歩み, 2003, 45-50
  17. 田内哲三, リンパ腫治療学総論:免疫療法, リンパ腫症例ノート, 大屋敷一馬, 向井清, 日本医学館, 2002, 44-46
  18. 田内哲三, 大屋敷一馬, Interferon-alfaによってcomplete cytogenetic responseが得られた後の治療, EBM血液疾患の治療2002-2003, 押味和夫, 別所正美, 岡本真一郎, 加藤淳, 中外医学社, 2002, 307-314
  19. Tauchi T, Ohyashiki K, Rearrangement of T cell receptor beta chain gene and its methylation status in B precursor acute lymphoblastic leukemis, Molecular Approaches to the Study and Treatment oh Human Disease, Yoshida TO, Wilson JM., Elsevier Netherland, 1992, 101-105

学術論文(原著・総説・症例報告・その他)

①原著

  1. Okabe S, Tauchi T, Tanaka Y, 2, Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells., Oncotarget, 2018, 9:32496-32506, IF: 5.168
  2. Inokuchi K, Nakayama K, Tauchi T, Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations., Leuk. Res., 2018, 65:74-79, IF: 2.319
  3. Oritani K, Ohishi K, Okamoto S, Tauchi T, Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis., Curr. Med. Res. Opin. 2018, 34:531-537,
  4. Kirito K, Okamoto S, Ohishi K, Tauchi T, Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with fibrosis. Int. J. Hematol., 2018, 107: 92-97, IF: 1.942
  5. Takahashi N, Tauchi T, Kitamura K, 2, Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic myeloid leukemia: the JALSG-STIM213 study. Int. J. Hematol., 2018, 107: 185-193, IF: 1.942
  6. Targeting peroxidase proliferator-activated receptors: a novel strategy for Philadelphia chromosome-positive leukemia cells. Leuk. Lymphoma., 2017, 58:2762-2764, IF: 2.644
  7. Katagiri S, Tauchi T, Ando K, 2, Low body weight and body mass index may be associated with muscloskeletal pain following imatinib discontinuation in chronic myeloid leukemia. Leuk. Res. Rep., 2017, 7:33-35,
  8. Tojo A, Kyo T, Yamamoto K, Tauchi T, Ponatinib in patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study. Int. J. Hematol., 106:385-397, IF: 1.942
  9. Asano M, Umezu T, Katagiri S, Tauchi T, Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors. Int. J. Hematol., 2017, 105:419-422, IF: 1.942
  10. Tauchi T, Okabe S, Katagiri S, 1, C, Targeting the hedgehog signaling pathway by glasdegib limits the self-renewal of MDS-drived induced potent stem cells (iPSC). J. Cancer. Sci. Ther., 2017, 9:479-484,
  11. Okabe S, Tauchi T, Tanaka Y, 2, Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells. Oncotarget., 2016, 16:53116-53126, IF: 5.068
  12. Ohyashiki K, Umezu T, Katagiri S, Tauchi T, Downregulation of plasma miR-215 in chronic myeloid leukemia patients with successful discontinuation of imatinib. Int. J. Mol. Sci., 2016, 17:570,
  13. Okabe S, Tauchi T, Tanaka Y, 2, Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation. J. Hematol. Oncol. 2015, 8:97, IF: 7.333
  14. Okabe S, Tauchi T, Tanaka Y, 2, Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Ableson tyrosine kinase inhibitors, against break point cluster resion-c-Ableson-positibe leukemia cells. Oncotarget., 2015, 6:20231-20240, IF: 5.168
  15. Jung CW, Shih LY, Xiao Z, Tauchi T, Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. Leuk. Lymphoma., 2015, 56:2067-2074, IF: 2.644
  16. Oritani K, Okamoto S, Tauchi T, A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japansese subset analysis. Int. J. Hematol., 101:295-303, IF: 1.942
  17. Okabe S, Tauchi T, Kimura S, 2, Combining the ABL1 kinase inhibitor ponatinib and histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia. PLoS One., 9:e89080, IF: 2.766
  18. Gotoh M, Yoshizawa S, Katagiri S, Tauchi T, Anovel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancy. Bone Marrow Transplant., 2014, 49:955-960, IF: 4.497
  19. Okabe S, Tauchi T, Katagiri S, 2, Combination of the ABL kinase inhibitor imatinib with Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells. J. Hematol. Oncol., 2014, 7:e37, IF: 7.333
  20. Gotoh M, Yoshizawa S, Katagiri S, Tauchi T, Human herpesvirus 6 reactivation on the 30th day after allogenic hematopoetic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease. Transpl. Infect. Dis., 2014, 16:440-449,
  21. Yoshimoto T, Mizoguchi I, Katagiri S, Tauchi T, Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. Oncoimmunology, 2014, 3:e28861, IF: 5.503
  22. Kuroda I, Inukai T, Zhang X, Tauchi T, BCR-ABL regurates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome positive leukemia. Oncogene., 2013,32: 1670-1681, IF: 6.854
  23. Katagiri S, Tuchi T, Okabe S, 2, C, Combination of ponatinib with hedgehog antagonist vismodegib for therapy –resistant BCR-ABL1-positive leukemia. Clin. Cancer Res., 2013, 19:1422-1432, IF: 10.199
  24. Okabe S, Tauchi T, Tanaka Y, 2, Activity of histon deacetylase inhibitors ans an Aurora kinase inhibitor in BCR-ABL-expressing cells. Cancer Cell Int. 2013, 13:186-1195, IF: 3.960
  25. CML Expert, Tauchi T, The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from perspective of a large group of CML experts.Experts of chronic myeloid leukemia. Blood., 2013, 121:4439-4442, IF: 15.132
  26. Okabe S, Tauchi T, Tanaka Y, 2, Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells. Biochem. Biophys. Res. Commun. 2013, 435:506-511, IF: 2.554
  27. Mizoguchi I, Yoshimoto T, Katagiri S, Tauchi T, Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci., 2013, 104:1146-1153, IF: 4.372
  28. Okabe S, Tauchi T, Tanaka Y, 2, Activity of omacetaxine mepesuccinate against ponatinib- resistant BCR-ABL-positive cells. Blood, 2013, 122:3086-3088, IF: 15.032
  29. Okabe S, Tauchi T, Tanaka Y, 2, Effects of Hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells. Stem Cell Dev., 2012, 21:2939-2948, IF: 3.315
  30. Ohnishi K, Nakajseko C, Takeuchi J, Tauchi T, Long-term outcome following imatinib therapy for chronic myelogenous leukemia with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci., 2012, 106: 1071-1078, IF: 4.372
  31. Ohyashiki K, Katagiri S, Tauchi T, Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br. J. Haematol., 2012, 157:254-256, IF: 5.128
  32. Okabe S, Tauchi T, Tanaka Y, 2, Dasatinib preferentially induced apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line. J. Hematol. Oncol., 2011, 4:32e, IF: 7.333
  33. Zang X, Inukai T, Akahane K, Tauchi T, Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosome-positive leukemia cells to TRAIL-mediated apoptosis. Leuk.Res., 2011, 35:940-949, IF: 2.319
  34. Tauchi T, Kizaki M, Okamoto S, 1, C, Seven-year follow up of patients receiving imatinib for the treatment of newly diagnosed chronic myeloid leukemia by TARGET system. Leuk. Res., 35:585-590, IF: 2.319
  35. Tauchi T, Okabe S, Ashihara K, 1, C, Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen. Oncogene, 2011, 30:2789-2797, IF: 6.854
  36. Okabe S, Tauchi T, Ohyashiki K, 2, Establishiment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation. Exp.Hematol., 2010, 38:765-772, IF: 2.436
  37. Gotoh M, Tauchi T, Yoshizawa S, 2, Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR-ABL mutation. Int. J. Hematol., 2010, 91:128-131, IF: 1.942
  38. Okabe S, Tauchi T, Ohyashiki K, 2, Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Ann. Hematol., 2010, 89:1081-1087, IF: 2.845
  39. Ohyashiki JH, Kobayashi C, Hamamura R, Tauchi T, The oral iron chelator deferasirox repress signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci., 2009, 100:970-977, IF: 4.372
  40. Okabe S, Tauchi T, Ohyashiki JH, 2, Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells. Biochem Biophys. Res. Commun., 2009, 380: 775-778, IF: 2.559
  41. Okabe S, Tauchi T, Ohyashiki K. 2, Characteristics of dasatinib- and imatinib-resistant chronic myelogenous cells. Clin. Cancer Res., 2008, 14: 6181-6186, IF: 10.199
  42. Kanada T, Okamoto S, Tauchi T, Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in chronic phase. Am. J. Hematol., 2008, 83: 835-839, IF: 5.303
  43. Yokoyama T, Miyazawa K, Naito M, Tauchi T, Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. Autophagy, 2008, 4:629-640, IF: 11.100
  44. Akahane D, Tauchi T, Okabe S, 2, C, Activity of a novel Aurora kinase inhibitor against the T315I mutation form of BCR-ABL: in vitro and in vivo studies. Cancer Sci., 99:1251-1257, IF: 4.372
  45. Okabe S, Tauchi T, Broxmeyer HE, 2, Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev., 2007, 16:503-514, IF: 3.315
  46. Nunoda K, Tauchi T, Takaku T, 2,C, Identification and functional signature of genes regulated by structurally different the ABL kinase inhibitors. Oncogene, 2007, 26: 4179-4188, IF: 6.854
  47. Tauchi T, Shin-ya K, Sashida G, 1, C, Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene, 2006, 25:5719-5725, IF: 6.854
  48. Okabe S, Tauchi T, Ohyashiki K. 2, Stromal-cell-derived factor-1/CXCL12-induced chemotaxis of a T cell line involves intracellular signaling through Cbl and Cbl-b and their regulation by Src kinases and CD45. Blood Cells Mol. Dis., 2006, 2:308-314, IF: 1.836
  49. Sumi M, Tauchi T, Sashida G, 2, Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients. Clin. Lab. Haematol., 2005, 6:416-417,
  50. Sashida G, Ohyashiki JH, Kubota N, Tauchi T., Marked telomere fluctuation of leukocytes during graft-versus-host disease in allogenic stem cell transplantation. Int. J. Mol. Med., 2005, 5: 883-888,
  51. Morishima Y, Ogura M, Nishimura M, Tauchi T., Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study. Int. J. Hematol., 2004, 80: 261-266, IF: 1.942
  52. Sumi M, Tauchi T, Sashida G, 2, A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. Int. J. Oncol., 2004, 24: 1481-1487, IF: 3.333
  53. Tauchi T, Sumi M, Nakajima A, 1, C, Bcl-2 antisense oligonucleotide, genasenseTM, is active against imatinib-resistant BCR-ABL-positive cells. Clin. Cancer Res., 2003, 9: 4267-4273, IF: 10.199
  54. Tauchi T, Shin-ya K, Sashida G, 1, C, Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: Involvement of ATM-dependent DNA damage response pathways. Oncogene, 2003, 22:5338-5347, IF: 6.854
  55. Sashida G, Ohyashiki JH, Nakajima A, Tauchi T., Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases. Clin. Cancer Res., 2003, 9:1489-1496, IF: 10.199
  56. Komatsu N, Watanabe T, Uchida M, Tauchi T., A member of forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J. Biol. Chem., 2003, 278: 6411-6419, IF: 4.010
  57. Miyazawa K, Nishimaki J, Katagiri T, Tauchi T., Thrombocytopenia induced by imatinib mesylate in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients ? Int. J. Hematol., 2003, 77:93-95, IF: 1.942
  58. Nakajima A, Tauchi T, Sumi M, 2, C, Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol. Cancer Ther., 2003, 2:219-224, IF: 6.854
  59. Nakajima A, Tauchi T, Sashida G, 2, C, Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of anti-telomerase therapy. Leukemia, 2003, 17:560-567, IF: 10.023
  60. Lawlor GF, Tauchi T, Ohyashiki K, 2, Enriched levels of erythropoietin in human umbilical cord blood stimulate hematopoietic progenitor cells. J. Biochem. Mol. Biophy., 2002, 6: 65-70,
  61. 川崎俊一、田内哲三、中嶋晃弘, 2, テロメラーゼ阻害による大腸癌細胞のテロメア短縮誘導及び細胞増殖抑制. 東医大誌, 2002, 60: 189-199,
  62. Tauchi T, Nakajima A, Sashida G, 1, C, Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin. Cancer Res., 2002, 8: 3341-3347, IF: 10.199
  63. Ohyashiki K, Kuriyama Y, Nakajima A, Tauchi T., Imatinib mesylate-induced hepato-toxicity in chronic myeloid leikemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia, 2002, 16: 2160-2161, IF: 10.023
  64. Misawa M, Tauchi T, Sashida G, 2, Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells. Int. J. Oncol., 2002, 1: 1087-1092, IF: 3.333
  65. Ohyashiki JH, Hayashi S, Yahata N, Tauchi T., Impaired telomere regulation mechanism by TRF1 (telomere-binding protein), but not TRF2 expression, in acute leukemia cells. Int. J. Oncol., 2001, 18: 593-598, IF: 3.333
  66. Nakajima A, Tauchi T, Ohyashiki K. 2, The impact of an ABL specific tyrosine kinase inhibitor, STI571 in Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. Leukemia, 2001, 15: 989-990, IF: 10.023
  67. Tauchi T, Yoshimura A, Ohyashiki K. 1, C, CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation: involvement of the ubiquitin proteasome pathway. Exp. Hematol., 2001, 29: 356-361, IF: 2.436
  68. Okabe S, Tauchi T, Yoshimura A. 2, C, Thrombopoietin induces an SH2-containing protein, CIS1, which binds to mpl: involvement of the ubiquitin protwasome pathway. Exp. Hematol., 1999, 27: 1542-1547, IF: 2.436
  69. Tauchi T, Okabe S, Miyazawa K, 1, The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells. Int. J. Oncol., 12: 1269-1276, IF: 3.333
  70. 田内哲三、岡部聖一、大屋敷一馬. 1, BCR-ABL変異体を用いた機能ドメインの解析とシグナル伝達. 臨床血液, 1998, 39: 81-82,
  71. Tauchi T, Miyazawa K, Feng GS, 1, C, A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules. J. Biol. Chem., 1997, 272: 1389-1394, IF: 4.010
  72. Tauchi T, Ohyashiki K, Yamashita Y. 1, SH2-containing phospho-tyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways. Int. J. Oncol., 1996, 11: 471-476, IF: 3.333
  73. Tauchi T, Damen JE, Toyama K., 1, Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation and promotes mitogenesis. Blood, 1996, 87: 4495-4501, IF: 15.032
  74. Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T., Tyrosine phosphorylation and activation of focal adhesion kinase by BCR-ABL oncoprotein. Exp. Hematol., 1995, 23: 1153-1159, IF: 2.436
  75. Tauchi T, Feng GS, Shen R, 1, Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J. Biol. Chem., 270: 5631-5635, IF: 4.010
  76. Tauchi T, Feng GS, Marshall MS, 1, The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells. J. Biol. Chem., 1994, 269: 25206-25211, IF: 4.010
  77. Tauchi T, Feng GS, Shen R, 1, SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase. J. Biol. Chem., 1994, 269: 15381-15387 IF: 4.010
  78. Tauchi T, Boswell HS, Leibowitz DS, 1, Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to Ras activation pathway. J. Exp. Med., 179: 167-175, IF: 10.790
  79. Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T., Role of p21Ras in p210bcr-abl transformation of murine myeloid cells. Blood, 1993, 82: 1838-1847, IF: 15.032
  80. Ohyashiki JH, Ohyashiki K, Kawakubo K, Tauchi T., The methylation status of the major breakpoint cluster region in human leukemia cells including Philadelphia chromosome-positive cells, is linked to the lineage of hematopoietic cells. Leukemia, 1993, 7: 801-807, IF: 10.023
  81. Ohyashiki JH, Ohyashiki K, Kawakubo K, Tauchi T., T-cell receptor b-chain gene rearrangement in acute myeloid leukemia always occurs at the allele that contains the undermethylated Jb1 region. Cancer Res., 1992, 2: 6589-6620, IF: 9.130
  82. Ohyashiki K, Fujieda H, Miyauchi J, Tauchi T., Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with chromosomal translocation t(17;19) the growth of which is inhibited by interleukin-3. Leukemia, 1992, 6: 321-331, IF: 10.023
  83. Ohyashiki JH, Ohyashiki K, Miyauchi J, Tauchi T., Immunogenotypes and clonal culture analysis in B-precursor acute lymphoblastic leukemia. Leukemia, 1992, 6: 240-245, IF: 10.023
  84. Ohyashiki K, Saito M, Ohyashiki JH, Tauchi T., Cytogenetic and clinical findings of myelodysplastic syndrome with a poor prognosis: An experience of 97 cases. Cancer, 1992, 70: 94-99, IF: 5.238
  85. 大屋敷純子、田内哲三、大屋敷一馬. 2, Ph陽性急性白血病における細胞起源の解析:免疫関連遺伝子再構成及びin vitroにおける各種サイトカインに対する反応性の検討. 臨床血液, 1991, 33: 333-337,
  86. Ohyashiki JH, Ohyashiki K, Tauchi T., Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a pilot study which raises important question. Leukemia, 1991, 5:611-614, IF: 10.023
  87. Ohyashiki K, Sasao I, Ohyashiki JH, Tauchi T, Clinical and cytogenetic characteristic of myelodysplastic syndromes developing myelofibrosis. Cancer, 1991, 68: 178-183, IF: 5.238
  88. Tauchi T, Ohyashiki JH, Ohyashiki K, 1, C, Methylation status of T-cell receptor beta chain gene in acute lymphoblastic leukemia with precursor B immunophenotypes: correlation with hypomethylation and gene rearrangement. Cancer Res., 1991, 51: 2917-2921, IF: 9.130
  89. Ohyashiki JH, Ohyashiki K, Tauchi T., Immunoglobulin and T-cell receptor gene rearrangements in Philadelphia chromosome positive chronic myelogenous leukemia. Leukemia., 1990, 4: 572-579, IF: 10.023
  90. Ohyashiki K, Ohyashiki JH, Iwabuchi H, Tauchi T., Presence of Philadelphia (Ph) chromosome -negative cells in Ph positive chronic myelogenous leukemia. Jap. J. Med., 1990, 29: 7-12,
  91. Ohyashiki K, Ohyashiki JH, Tauchi T., Hu-ets-1 gene in myelodysplastic syndrome with chromosome change at 11q23. Cancer Genet. Cytogenet., 1990, 45: 73-80, IF: 1.924
  92. Ohyashiki K, Ohyashiki JH, Iwabuchi H, Tauchi T., Philadelphia chromosome-positive chronic myelogenous leukemia deleted fusion of BCR and ABL genes. Jpn. J. Cancer Res., 1990, 81: 35-42, IF: 4.372

②総説

  1. Tauchi T, Ohyashiki K. 1,C, The second generation of BCR-ABL tyrosine kinase inhibitors. Int. J. Hematol., 2006, 83: 294-300, IF: 1.942
  2. Tauchi T, Ohyashiki K. 1, C, Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia. Int. J. Hematol., 2004, 9: 434-40, IF: 1.942
  3. Tauchi T, Ohyashiki K. 1, C, Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk. Res. 2004, Suppl 1: s39-45, IF: 2.319
  4. Ohyashiki JH, Sashida G, Tauchi T. Telomeres and telomerase in hematologic neoplasia. Oncogene, 2002, 21: 680-687, IF: 6.854
  5. Tauchi T, Miyazawa K, Ohyashiki K. 1, A coiled-coil tetramerization domain of BCR-ABL is essential for the interaction of SH2-containing signal transduction molecules. Human Cell, 1996, 9: 333-336, IF: 2.109
  6. Tauchi T, Broxmeyer HE. 1, BCR-ABL signal transduction. Int. J. Hematol., 1995, 61: 105-112, IF: 1.942

③症例報告

  1. 片桐誠一朗, 田内哲三, 梅津知宏, 2, Imatinib中止後の再発にimatinibとIFNa併用療法を行い無治療で分子寛解を維持するBIM欠失多型のCML. 臨床血液, 2015, 56: 216-219
  2. 住昌彦, 田内哲三, 高久智生, 2, インターフェロンalfaが有効であったと考えられる真性赤血球増加症からdel(20q)を伴う急性骨髄性白血病. 臨床血液, 2006, 46: 1208-1212
  3. Sumi M, Tauchi T, Sashida G, 2, Natural killer cell lymphoma in the duodenum. Leuk. Lymphoma., 2004, 44: 201-204, IF: 2.644
  4. 住昌彦, 田内哲三, 指田吾郎, 2, Imatinib Mesylateにより高度な汎血球減少が蔓延した慢性骨髄性白血病. 臨床血液, 2002, 43:868-870
  5. 内海健太, 長手聡, 國澤晃, 田内哲三, 全身に多発するリンパ節腫脹を伴うサルコイドーシスの一例. 東京内科医会会誌, 2001, 16:213-216
  6. Yahata N, Iwase O, Iwama A, Tauchi T., Chronic lymphocytic leukemia complicated by plasmacytoma originating from different clonees. Leuk. Lymphoma, 2000, 39:203-207, IF: 2.644
  7. 久保田尚志, 鈴木章孝, 林重文, 田内哲三, 骨髄移植後、DLTが有効であった急性リンパ性白血病再発例. 日本内科学会誌, 2000, 89:131-133
  8. 小田和昌彦, 川西慶一, 安藤恵子, 田内哲三, 末期に急激な骨髄線維症と血球貪食症候群様の臨床所見を呈した真性赤血球増加症合併成人T細胞性白血病. 臨床血液, 2000, 41:1254-1259
  9. 岡部聖一, 八幡尚之, 田内哲三, 骨髄線維化を伴った好酸球増加症の一例. 臨床血液, 1999, 40:420-422
  10. Shimamoto T, Ohyashiki K, Nehashi Y, Tauchi T, Leukemic phase of intermediate non-Hodgkin's lymphoma with cells showing different matured stages in invaded various organs. Internal Med., 1992, 31: 553-556
  11. Kawakubo K, Ohyashiki JH, Ohyashiki K, Tauchi T, Restoration of cytogenetically normal marrow cells after remission of lymphoblastic crisis in a case of Ph positive CML treated with alpha-interferon. Cancer Genet. Cytogenet., 1992, 58:165-168, IF: 1.924
  12. Murakami T, Ohyashiki K, Kodama A, Tauchi T, Cromosomal translocation (2;16)(p11;q22) and trisomy 22 in acute myelogenous leukemia (FAB M2) with bone marrow eosinophilia. Cancer Gen. Cytogenet., 1991, 56: 281-283, IF: 1.924
  13. Tauchi T, Ohyashiki K, Ohyashiki JH, 1, Acute lymphoblastic leukemia with azurophilic granules that contain ultrastractural myeloperoxidase activity. Am J. Hematol., 1991, 36: 288-290, IF: 5.303
  14. Tauchi T, Ohyashiki K, Kodama A, 1, Two sdditional acute nonlymphocytic leukemia patients with a sole chromosome abnormality of trisomy 4. Leuk. Lymphoma, 1990, 2: 131-135 , IF: 2.644
  15. 田内哲三, 鈴木章孝, 藤邑俊克, 1, Protein Aカラムによる血漿交換が奏功したと思われる難治性ITPの一例. 臨床血液, 1989, 30: 1289-1293
  16. 宮澤啓介, 大屋敷純子, 田内哲三, Gaucher様細胞を認めた慢性骨髄性白血病リンパ芽球性急性転化の一例. 臨床血液, 1988, 29:1488-1492
  17. 外山圭助, 田内哲三, 藤枝広巳, 2, 発症後17年経過しATG療法が奏功した重症再生不良性貧血の一例. 臨床血液, 1988, 29:85-90

④その他の学術論文

  1. Kiguchi T, Tauchi T, Ito Y, 2, Compliance with taking imatinib mesylate in patients with chronic myelogenous leukemia in the chronic phase. Leuk. Res., 2008, 33:506-508, IF: 2.319
  2. Akahane D, Ito Y, Sumi M, Tauchi T, Relapse of chronic myelogenous leukemia-chronic phase 14 years after allogenic hematopoietic stem cell transplantation. Int. J. Hematol., 2008, 88:119-120, IF: 1.942
  3. Ohyashiki K, Kiguchi T, Ito Y, Tauchi T, Isolated erythrocythemia: a distinct entity or sub-type of polycythemia vera? Jpn. J. Clin. Oncol., 38: 230-232
  4. Ohyashiki K, Tauchi T, Kuroda M, 2, Recurrent chromosomal aberration at 12q15 in chronic idiopathic myelofibrosis with or without JAK2(V617F) mutation. Leukemia, 2007, 21:1578-1580, IF: 10.023
  5. Ohyashiki K, Akahane D, Gotoh A, Tauchi T., Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status. Leukemia, 2007, 21: 2544-2545, IF: 10.023
  6. Jankipersadsing V, Tauchi T, Ohyashiki K. 2, Spontaneous regression of pulmonary infiltration of adult T-cell leukemia/lymphoma. Int. J. Hematol.,2007, 85: 173-174, IF: 1.942
  7. Okabe S, Tauchi T, Ishii Y, 2, Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy. Int. J. Hematol.,2007, 85: 173-174, IF: 1.942
  8. Iguchi T, Sashida G, Kawakubo K, Tauchi T, De novo appearance of t(7;13)(q10;q33) in the leukemic phase of myelodysplastic syndrome: a case report. Jpn. J. Clin. Oncol., 2004, 32: 35-36,
  9. Sashida G, Tauchi T, Kimura Y, 2, Trisomy 15 as a single autosomal abnormality in a patient with unclassifiable myelodysplastic syndromes. Cancer Genet. Cytogenet., 2001, 127: 91-92, IF: 1.924
  10. Sashida G, Tauchi T, Ando K, 2, Translocation (5;18) in a patient with myelodysplastic syndrome: refractory anemia with excess blasts in transformation. Cancer Genet. Cytogenet., 2000, 121: 230-231, IF: 1.924
  11. Yahata N, Tauchi T, Kimura Y, 2, Double Philadelphia chromosomes in acute lymphocytic leukemia. Cancer Genet. Cytogenet., 2000, 121: 101-102, IF: 1.924
  12. Sashida G, Tauchi T, Katagiri T, 2, Transformation of severe aplastic anemia into myelodysplastic syndrome with monosomy 7: monoclonal origin detected by HUMARA gene analysis during the aplastic anemia phase. Hematologica, 2000, 85: 665-666, IF: 9.090
  13. Ito Y, Kuriyama Y, Tauchi T, Apatient with pure red cell aplasia and Good's syndrome. Hematologica, 1999, 84: 1048-1049, IF: 9.090
  14. Tauchi T, Iwama A, Kaku H, 1, Remission of pure-red-cell aplasia associated with operative cure of lung cancer. Am. J. Hematol., 1999, 61: 157-158, IF: 5.303
  15. Yahata N, Ohyashiki K, Iwama H, Tauchi T, Chronic myelomonocytic leukemia in a patient with antiphospholipid syndrome: First case report. Leuk. Res., 1997, 31:889-890, IF: 2.319
  16. 根橋良雄, 岩渕広高, 津田明端, 田内哲三, 巨核球系細胞の増生とt(3;4)染色体異常を有し、骨髄線維化を伴って白血化したMDSの一例. 日本内科学会雑誌, 1991, 80:759-760
  17. Tauchi T, Ohyashiki K, Ohyashiki JH, 1, CD4+CD56+ acute monoblastic leukemia. Am. J. Hematol., 1990, 34: 228-229, IF: 5.303
  18. Tauchi T, Ohyashiki JH, Fujieda H, 1, Treatment of anemia of rheumatoid arthritis with recombinant human erythropoietin. Br. J. Rheumat., 26: 235-236,
  19. 根橋良雄, 嶋本隆司, 塩田真美, 田内哲三, 巨核芽球性急性転化時に腫瘤形成を認め腫瘤内に急性転化クローンを認めた慢性骨髄性白血病の一例. 日本内科学会雑誌, 1990, 79:113-114

学術刊行物

①研究報告

  1. 田内哲三, 大屋敷一馬, テロメラーゼを標的とした難治性白血病の分子標的療法の開発, 平成18年度厚生労働省がん研究助成金研究報告書, 2007, 529-531
  2. 田内哲三, 大屋敷一馬,テロメラーゼを標的とした難治性白血病の分子標的療法の開発, 平成17年度厚生労働省がん研究助成金研究報告書, 2006, 505-508
  3. 田内哲三, 大屋敷一馬,テロメラーゼを標的とした難治性白血病の分子標的療法の開発, 平成16年度厚生労働省がん研究助成金研究報告書, 2005, 499-502
  4. 田内哲三, 大屋敷一馬,テロメラーゼを標的とした難治性白血病の分子標的療法の開発, 平成15年度厚生労働省がん研究助成金研究報告書, 2004, 511-515
  5. 田内哲三, 大屋敷一馬,テロメラーゼ阻害分子による婦人科癌の分子標的療法, 平成13年度厚生労働省がん克服戦略研究事業総括、分担研究報告, 2002, 32-34
  6. 田内哲三, 大屋敷一馬,テロメラーゼ阻害分子による造血器腫瘍の分子標的療法:テロメスタチン、STI571, 平成12年度厚生労働省がん克服戦略研究事業総括、分担研究報告 2001, 28-29

②その他の学術刊行物

  1. 田内哲三, MDSに由来するiPS細胞の樹立と臨床応用, 血液内科, 2015, 71: 577-580
  2. 田内哲三, 高齢者の分子標的治療薬を投与する際の注意点, 血液内科, 2015, 70: 462-465
  3. 田内哲三, CML治療に対するTKI療法においての注意すべき有害事象, 血液内科, 2015, 70:416-419
  4. 田内哲三, 岡部聖一, オーロラキナーゼ阻害剤の臨床への導入, 血液内科, 2015, 70:176-179
  5. 田内哲三, 大屋敷一馬, MPDでの治療薬の開発と新たに分った分子異常, 腫瘍内科, 2014, 14:589-595
  6. 田内哲三, 大屋敷一馬,慢性骨髄性白血病治療におけるイマチニブ抵抗性の機序とその克服, 癌と化学療法2011, 38:749-753
  7. 岡部聖一, 田内哲三, 大屋敷一馬, 分子用的治療薬 ダサチニブ, Biotherapy, 2010, 24: 275-278
  8. 岡部聖一, 田内哲三, 大屋敷一馬, オーロラキナーゼ阻害剤, 血液フロンンティア, 2010, 20: 1541-1544
  9. 岡部聖一, 田内哲三, 大屋敷一馬, 分子用的治療薬 ニロチニブ, Biotherapy, 2010, 24:412-415
  10. 岡部聖一, 田内哲三, 大屋敷一馬, ABLキナーゼ阻害剤導入後のCMLの予後予測, 血液腫瘍科, 2010, 61:387-390
  11. 田内哲三, 大屋敷一馬, 慢性骨髄性白血病に対するチロシンキナーゼ阻害剤の開発 現状の到達点と今後の課題, 血液腫瘍科, 2010, 61:531-535
  12. 田内哲三, 大屋敷一馬, 白血病治療の最前線, 内科, 2010, 106:261-266
  13. 岡部聖一, 田内哲三, 大屋敷一馬, 慢性骨髄性白血病の病態と治療, 分子細胞治療, 2008, 12:18-22
  14. 田内哲三, 大屋敷一馬, 抗がん剤を知る:メシル酸イマチニブ, 臨床腫瘍プラクチィス, 2008, 3:412-416
  15. 田内哲三, 大屋敷一馬,イマチニ抵抗性慢性骨髄性白血病の治療, 癌と化学療法, 2008, 30: 1065-1070
  16. 岡部聖一, 田内哲三, 大屋敷一馬, メシル酸イマチニブ:抗がん剤を知る-薬剤選択のための知識-, 臨床腫瘍プラクティス, 2007, 3: 412-416
  17. 田内哲三, 大屋敷一馬, AMLにおける新規分子標的薬の展望, 血液・腫瘍科, 2007, 55: 221-227
  18. 田内哲三, 大屋敷一馬, 慢性骨髄性白血病治療の新展開, 日本臨床・増刊号, 2007, 65: 617-621
  19. 田内哲三, 大屋敷一馬, 造血器腫瘍の分子標的療法:概論, 日本臨床・増刊号, 2007, 65: 395-398
  20. 田内哲三, 大屋敷一馬, 慢性骨髄性白血病の病因・病態解析-最近の展開-, 日本臨床・増刊号, 2007, 65: 75-79
  21. 田内哲三, 大屋敷一馬, 慢性骨髄性白血病の再発とイマチニブ耐性機構, Molecular Medicine, 2005, 42: 873-878
  22. 田内哲三, 大屋敷一馬, imatinibによる好酸球増加症の治療, 臨床医, 2005, 31: 1947-1950
  23. 田内哲三, 大屋敷一馬, イマチニブ耐性化機構とその克服-特集:慢性骨髄増殖性疾患, 血液フロンンティア, 2005, 15: 27-34
  24. 田内哲三, 大屋敷一馬, 慢性骨髄性白血病, 臨床医, 2004, 30: 2170-2171
  25. 田内哲三, 大屋敷一馬, その他の疾患によるイマチニブ療法, 血液フロンンティア, 2004, 14: 99-104
  26. 田内哲三, 大屋敷一馬, メシル酸イマチニブ, カレントテラピー, 2004, 22:98
  27. 田内哲三, 大屋敷一馬, GRN163によるテロメラーゼを標的としたCMLの分子標的療法, 医学のあゆみ, 2003, 207: 1009-1010
  28. 田内哲三, 大屋敷一馬, 慢性骨髄性白血病, 総合臨床, 2003, 52: 2570-2574
  29. 中嶋晃弘, 田内哲三, 大屋敷一馬, STI-571-白血病-特集:分子標的治療薬の臨床評価, 癌と化学療法, 2003, 30: 1065-1070
  30. 田内哲三, 大屋敷一馬, Ras阻害剤によるAMLの分子標的療法, 血液・腫瘍科, 2003, 46: 415-422
  31. 田内哲三, 大屋敷一馬,テロメアと慢性骨髄性白血病, 血液・腫瘍科, 2003, 46: 208-212
  32. 田内哲三, 大屋敷一馬, チロシンキナーゼ阻害剤(imatinib mesylate)耐性克服に向けて, 臨床医, 2002, 28: 2143-2147
  33. 久富寿, 大屋敷一, 大屋敷純子, 田内哲三, Tlomerase reverse transcriptase (hTERT) mRNA の新規SPLICING VARIANTSの発見と発現調査, SRL 宝函, 2002, 26:166-168
  34. 田内哲三, 大屋敷一馬, チロシンキナーゼ阻害剤 ImatinibによるPh陽性白血病の分子標的療法, 医学のあゆみ, 2002, 202: 49-54
  35. 田内哲三, 大屋敷一馬, チロシンキナーゼ阻害剤 STI571によるPh陽性白血病の分子標的療法, 遺伝子医学, 2002, 6: 221-224
  36. 田内哲三, 大屋敷一馬, 抗腫瘍薬治療の最前線, 臨床医, 2002, 28: 1716-1719
  37. 田内哲三, 大屋敷一馬, Ph陽性急性リンパ性白血病治療の新展開, 血液フロンンティア, 2002, 12: 75-81
  38. 田内哲三, 大屋敷一馬, 慢性骨髄性白血病の治療戦略, Medicina, 2001, 38: 220-222
  39. 八幡尚之, 大屋敷純子, 嶋本隆司, 田内哲三, チロシンキナーゼ阻害剤 STI571による慢性骨髄性白血病の分子標的療法, 血液・腫瘍科, 2001, 42: 409-415
  40. 中嶋晃弘, 田内哲三, 大屋敷一馬, テロメラーゼ活性による肺がんの診断-臨床応用への可能性, 呼吸, 2001, 20: 652-658
  41. 田内哲三, 大屋敷一馬, チロシンキナーゼ阻害剤 STI571による慢性骨髄性白血病の分子標的療法, 分子細胞治療, 2001, 17: 337-342
  42. 田内哲三, 大屋敷一馬, 慢性骨髄性白血病の治療戦略:診断と治療の現状と展望, Medicina, 2000, 37: 44-52

5-a 国際学会

①シンポジウム

  1. Tauchi T, Miyazawa K, Ohyashiki K. The tertamerization domain of BCR-ABL is essential for the interaction of SH2-containing signal transduction molecules. 4th Japan-China Symposium of Hematology under the Cooperation of two Society. 1996.9.
  2. Tauchi T, Miyazawa K, Ohyashiki K. A coiled-coil tertamerization domain of BCR-ABL is essential for the interaction of SH2-containing signal transduction molecules. 5th International Congress of Human Cell and Cell Culture (Symposium), 1996. 8

②一般演題及びポスター発表

  1. Tauchi T, Okabe S, Katagiri S, ABL001 with catalytic-site inhibitors limit the CML immature cell population: Re-differentiation of CML-iPSCs study. 59th Annual Meeting of American Society of Hematology, 2017. 12
  2. TTauchi T, Okabe S, Katagiri S, Combining Effects of the SMO Inhibitor and Jak1 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC), 58th Annual Meeting of American Society of Hematology, 2016. 12
  3. Tauchi T, Okabe S, Katagiri S, Targeting the Hedgehog Signaling Pathway By PF-04449913 Limits the Self-Renewal of MDS-Derived Induced Potent Stem Cells (iPSC): Molecular Mechanisms, 57th Annual Meeting of American Society of Hematology, 2015. 12
  4. Tauchi T, Okabe S, Katagiri S, Activity of the stemness inhibitor, BBI608, on the self-renewal of BCR-ABL1 positive leukemia cells, 56th Annual Meeting of American Society of Hematology, 2014. 12
  5. Tauchi T, Okabe S, Katagiri S, Targeting the dopamine receptor signaling limits the self-renewal of BCR-ABL1 positiveleukemia cells: Molecular mechanisms, 55th Annual Meeting of American Society of Hematology, 2014. 12
  6. Tauchi T, Okabe S, Katagiri S, Targeting the hedgehog signaling pathway limits the self-renewal of BCR-ABL1 positive leukemia cells: molecular mechanismsa, 54th Annual Meeting of American Society of Hematology, 2013. 12
  7. Okabe S, Tauchi T, Katagiri S, Activity of the Aurora kinase inhibitor, MLN8237 alone or in combination with ponatinib against imatinib-resistant BCR-ABL-positive cells, 53th Annual Meeting of American Society of Hematology, 2012. 12
  8. Tauchi T, Okabe S, Katagiri S, Combined effects of a Pan-ABL1kinase inhibitor, ponatinib and dasatinib against T315I mutant forms of BCR-ABL: In vitro and in vivo studies, 52th Annual Meeting of American Society of Hematology, 2011. 12
  9. Tauchi T, Okabe S, Katagiri S, Seven-year follow-up of patients receiving imatinib for the treatment of chronic myekogenous leukemia by the TARGET system, 52th Annual Meeting of American Society of Hematology, 2010. 12
  10. Tauchi T, Okabe S, Katagiri S, Commbined effectd of hedgehog pathway inhibitor LDE225 and nilotinib in a random mutagenesis screen, 52th Annual Meeting of American Society of Hematology, 2010. 12
  11. Tauchi T, Okabe S, Ashihara E, Combined effects of novel Heat Schok Protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen, 51th Annual Meeting of American Society of Hematology, 2009.12
  12. Tauchi T, Akahabe D, Okabe S, Combined effects of novel heat shock protein inhibitor, NVP-AUY922 and nilotinib against mutant forms of BCR-ABL, 50th Annual Meeting of American Society of Hematology, 2008.12
  13. Tauchi T, Shin-ya K, Sashida G, Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia., 46th Annual Meeting of American Society of Hematology, 2004.12
  14. Tauchi T, Shin-ya K, Nakajima A, Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: Involvement of ATM-dependent DNA damage response pathways., 45th Annual Meeting of American Society of Hematology, 2003.12
  15. Tauchi T, Nakajima A, Sashida G, Bcl-2 antisense oligonucleotide, genasenseTM, is active against imatinib-resistant BCR-ABL-positive cells. 43th Annual Meeting of American Society of Cancer Research, 2002.4
  16. Tauchi T, Nakajima A, Sashida G, Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. 41th Annual Meeting of American Society of Hematology, 2000.12
  17. Tauchi T, Matozaki T, Ohyashiki K, Role of SHPS-1 in BCR-ABL mediated transformation: Involvement of Ras activation pathways. 40th Annual Meeting of American Society of Hematology,1999.12
  18. Tauchi T, Yoshimura A, Ohyashiki K, CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation: involvement of the ubiquitin proteasome pathway. 39th Annual Meeting of American Society of Hematology, 1998.12
  19. Tauchi T, Miyazawa K, Feg GS, A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules. 37th Annual Meeting of American Society of Hematology, 1996.12
  20. Tauchi T, Feng GS, Shen R, SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase. 33th Annual Meeting of American Society of Hematology, 1993.12
  21. その他21編

5-b 国内学会、地方会及び研究会

①特別講演、招待講演、シンポジウム、パネルディスカッション及びワークショップ

  1. 田内哲三, CML治療における有害事象, 第80回日本血液学会総会教育講演, 2018.10.
  2. 田内哲三, 第三世代ABLチロシンキナーゼ阻害剤, 第75回日本血液学会総会教育講演, 2013. 10.
  3. Ph陽性白血病の新規治療の試み:ABL TKIsと分子標的薬との併用, 74回日本血液学会総会シンポジウム, 2012. 10.
  4. 田内哲三, 慢性骨髄性白血病の分子病態, 第72回日本血液学会総会教育講演, 2010. 9.
  5. 田内哲三, ACTIVITY OF A NOVEL AURORA KINASE INHIBITOR AGAINST T315I MUTANT FORM OF BCR-ABL: IN VITRO AND IN VIVO STUDIES. 第69回日本血液学会総会シンポジウム, 2007. 9.
  6. 田内哲三, 布田晃介, 高久智生, Bcl-2関連分子阻害剤、ABT-737のDasatinib 耐性CML細胞に対する生物活性, 第68回日本血液学会総会ワークショップ, 2006. 9.
  7. 布田晃介, 田内哲三, 高久智生, 多分子標的SRC/ABLチロシンキナーゼ阻害剤、dasatinibによる細胞内情報伝達分子の制御:メシル酸イマチニブとの比較検討, 第68回日本血液学会総会ワークショップ, 2006.9.
  8. 田内哲三, 布田晃介, 高久智生, CML細胞におけるメシル酸イマチニブ耐性化とBMS-354825耐性化機序の比較検討, 第67回日本血液学会総会ワークショップ, 2005.9.
  9. 住昌彦, 田内哲三, 中嶋晃弘, テロメラーゼ阻害剤、SOT-095による急性白血病の分子標的療法: in vivoでの有効性の検討, 第65回日本血液学会総会ワークショップ, 2003. 8.
  10. 田内哲三, チロシンキナーゼ阻害剤と慢性骨髄性白血病, 第65回日本血液学会総会教育講演, 2003. 8.
  11. 住昌彦, 田内哲三, 中嶋晃弘, G-quadruplex相互作用分子、テロメスタチンによる急性白血病の分子標的療法, 第64回日本血液学会総会ワークショップ, 2002.9.
  12. 田内哲三, 中嶋晃弘, 住昌彦, Genasense (Bcl2 antisense oligonucleotide)によるPh陽性白血病の分子標的療法, 第64回日本血液学会総会ワークショップ, 2002.9.
  13. 田内哲三, 新家一男, 指田吾郎, G-quadruplex相互作用テロメラーゼ阻害分子によるPh陽性白血病の分子標的療法, 第64回日本血液学会総会ワークショップ, 2002.9.
  14. 田内哲三, 中嶋晃弘, 住昌彦, テロメラーゼ阻害分子によるPh陽性白血病の治療戦略, 第63回日本血液学会総会ワークショップ, 2001.3.
  15. 中嶋晃弘, 田内哲三, 大屋敷一馬, チロシンキナーゼ阻害剤STI571によるPh陽性白血病のアポトーシス誘導, 第59回日本癌学会シンポジウム, 2000.9.
  16. 田内哲三, 中嶋晃弘, 住昌彦, hTERTを分子標的とする白血病の遺伝子治療の基礎研究, 第59回日本癌学会シンポジウム, 2009.9.
  17. 中嶋晃弘, 田内哲三, 大屋敷一馬, SHPS-1によるBCR-ABL腫瘍形成能の制御, 第62回日本血液学会総会ワークショップ, 2000.3.
  18. 田内哲三, 吉村昭彦, 大屋敷一馬, CIS1によるBCR-ABL腫瘍形成能の制御, 第61回日本血液学会総会ワープショップ, 1999.4.
  19. 田内哲三, 宮澤啓介, 大屋敷一馬, BCR-ABL変異体を用いた機能ドメインの解析と細胞内分子との相互作用, 第16回血液幹細胞シンポジウム, 1996. 10.
  20. 田内哲三, BCR-ABLのシグナル機構, 第57回日本血液学会総会シンポジウム, 1995.7.
  21. その他、8編

②一般演題及びポスター発表等

  1. 田内哲三, 片桐誠一郎, 岡部聖一, Combining effects of the SMO inhibitor and Jak1 inhibitor in MDS-derived induced potent stem cells, 第79回日本血液学会総会, 2017.10
  2. 田内哲三, 岡部聖一, 大屋敷一馬, Hedgehog Signaling Pathway Inhibitor, PF-04449913 Limits the Self-Renewal of MDS-Derived Induced Potent Stem Cells (iPSC): Molecular Mechanisms, 第78回日本血液学会総会, 2016.10
  3. 田内哲三, 岡部聖一, 片桐誠一郎, Activity of the stemess inhibitor, BBI608, on the self-renewal of BCR-ABL1 positive leukemia cells. 第77回日本血液学会総会, 2015.10
  4. 田中裕子, 岡部聖一, 田内哲三, Antitumor activity of phosphoinositide-3-kinases inhibitor, copanlisib in multiple myeloma cells, 第77回日本血液学会総会, 2015.10
  5. 片桐誠一郎, 田内哲三, 梅津知宏, Predictive factors for successful treatment discontinuation of CML patients, 第77回日本血液学会総会, 2015.10
  6. 岡部聖一, 田内哲三, 田中裕子, Posphoinositide 3 kinase inhibitor, copanlisib for the treatment of Ph positive leukemia cells, 第77回日本血液学会総会, 2015.10
  7. 田内哲三, 片桐誠一郎, 岡部聖一, Targeting the domapine receptor signal limits the self-renewal of BCR-ABL1 positive leukemia, 第76回日本血液学会総会, 2014.10
  8. 岡部聖一, 田内哲三, 片桐誠一郎, The PLK inhibitor rigosertib in combination with ABL kinase inhibitor against BCR-ABL1-positive cells, 第76回日本血液学会総会, 2014.10
  9. 織谷健二, 岡本真一郎, 田内哲三, Efficacy and safety of ruxolitinib in Japanese patients with myelokfibrosis (MF), 第76回日本血液学会総会, 2014.10
  10. 田中裕子, 岡部聖一, 田内哲三, Therapeutic potential of fingolimod and sphingosine kinase inhibitors in myeloma cells, 第76回日本血液学会総会, 2014.10
  11. 片桐誠一郎, 田内哲三, 斉藤優, Long term follow up after imatinib cessation for patients in deep molecular response, 第76回日本血液学会総会, 2014.10
  12. 田内哲三, 東條有伸, 中前弘明, Preliminary report of a phase 1/2 study of ponatinib in Japanese patients with Ph+ leukemia, 第75回日本血液学会総会, 2013.10
  13. 田内哲三, 片桐誠一郎, 岡部聖一, Targeting the hedgehog signaling pathway limits the self-renewal of BCR-ABL1 positive leukemia, 第75回日本血液学会総会, 2013.10
  14. 岡部聖一, 田内哲三, 片桐誠一郎, Activity of the aurora kinase inhibitor, MLN8237(alisertib) and ponatinib against BCR-ABL positive cells, 第75回日本血液学会総会, 2013.10
  15. 岡部聖一, 田内哲三, 片桐誠一郎, Activity of imatinib and Jak kinase inhibitor: a potential treatment for Ph-positive leukemia cells, 第75回日本血液学会総会, 2013.10
  16. 田中裕子, 岡部聖一, 吉澤成一郎, 田内哲三, Serum sphingsine-1-phosphate is possible to be an available biomarker for multiple myeloma, 第75回日本血液学会総会, 2013.10
  17. 片桐誠一郎, 梅津知宏, 大屋敷純子, 田内哲三, BCL2L11 (BIM)欠失多型は慢性骨髄性白血病におけるイマチニブ中止を規定する, 第110回日本内科学会総会, 2013.7
  18. 田内哲三, 木崎昌彦, 岡本真一郎, The TARGET system provides more practical and general features compared with IRIS study, 第73回日本血液学会総会, 2011.10.
  19. 田内哲三, 岡部聖一, 木村晋也, Combined effects of the hedgehog inhibitor LDE225 and nilotinib in a randam mutagenesis screen, 第73回日本血液学会総会, 2011.10
  20. 岡部聖一, 田内哲三, 大屋敷一馬, Characteristics of nilotinib and imatinib resistant chronic myeloid leukemia cells, 第73回日本血液学会総会, 2011.10
  21. その他、142編

③共催セミナー等

  1. Tetsuzo Tauchi, Translational Research in an Era of Targeted Therapy: Lesson from ABL TKIs, The 18th Word Congress of Basic and Clinical Pharmacology, Lucheon Seminr 8, 2018.7
  2. 田内哲三, 骨髄増殖性腫瘍治療のパラダイムシフト, Novartis Hematology Web Seminar, 2017.11
  3. 田内哲三, CML治療の現状と今後の展望, 中越血液疾患懇話会, 2017.11
  4. 田内哲三, 慢性骨髄性白血病ガイドラインとTKIの長期安全性, 第79回日本血液学会総会BMSコーポレイトセミナー, 2017.10
  5. 田内哲三, Bosutinibによる慢性期CMLの治療戦略, Hematology Seminar, 2017.9
  6. 田内哲三, Treatment Free Remissionに向けた慢性期CMLの治療戦略, Novartis Hematology Seminar, 2017.3
  7. 田内哲三, 骨髄増殖性腫瘍治療のパラダイムシフト, 広島 Hematology Forum, 2017.2
  8. 田内哲三, 慢性期CMLに対する第2世代 ABL TKIsの治療効果と安全性, 第14回近畿Hematology Club, 2016.11
  9. 田内哲三, Bosutinib投与によりDMRを獲得した肺高血圧併発CML-CP症例, ボシュリフ症例検討会, 2016.11
  10. 田内哲三, CML及びPh ALLに対する第3世代ABL TKI (Ponatinib)の使用経験, 大塚製薬社内セミナー, 2016. 8
  11. 田内哲三, 慢性期CMLに対する第2世代ABL TKIsの治療効果と安全性, Novartis Hematology Forum 2016, 2016.7
  12. 田内哲三, 慢性期CMLに対する第2世代ABL TKIsの治療効果, CML Expert Conference横浜, 2016. 7
  13. 田内哲三, 慢性期CMLに対する第2世代ABL TKIsの治療効果と安全性, CML / 鉄過剰症 学術講演会 山形, 2016.7
  14. 田内哲三, 慢性期CMLに対する第2世代ABL TKIsの治療効果と安全性, 香川最新血液セミナー MPN- Chronic Myeloid Leukemia -, 2016.4
  15. 田内哲三, 慢性期CMLに対する第2世代ABL TKIsの治療効果と安全性, 第11回BMS Hematological Web セミナー Chronic Myeloid Leukemia -, 2016.2
  16. 田内哲三, 慢性期CMLに対する第2世代ABL TKIsの治療効果, CML Expert Matters in East Japan, 2015.11
  17. 田内哲三, 慢性骨髄性白血病治療の現状と展望, ファイザーOncology社内研究会, 2015.2
  18. 田内哲三, 癌性幹細胞を標的としたPh陽性白血病の治療戦略, Tokyo Hematology Seminor, 2014.9